WASHINGTON – Interim findings from a phase 1b/2 study indicate the combination shows promising clinical activity and...
News from the FDA/CDC
Prevalence dropped to 14% among adults in 2017, but control strategies need to “address the diversity of tobacco products.”
The approval was based on an overall response rate of 48% in patients previously treated with one or more ALK kinase inhibitors.
Pembrolizumab is now approved for use in combination with carboplatin and either paclitaxel or nab-paclitaxel for the first-line treatment of...
From the Journals
MUNICH – Erlotinib for stage IIIA (N2) NSCLC may increase progression-free survival, but clinical benefits fall...
TORONTO – Concurrent atezolizumab and chemoradiation therapy is safe and showed promising efficacy in LA-NSCLC in...
The ALTA-1L trial showed a 51% reduction in progression-free survival with brigatinib versus crizotinib in ALK-positive NSCLC.
Patients at high risk for lung cancer are recommended to have an annual low-dose CT scan after a negative baseline scan.
The drug has a recommended dose of 45 mg once daily with or without food.